A Phase 2 interventional study of Brivaracetam intravenous solution and Brivaracetam oral tablets in Nonconvulsive Electrographic Seizures, sponsored by UCB BIOSCIENCES, Inc.. Terminated at 2 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-07-11.
Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Seizures by UCB S.A. — 3 open to participants now, 4 under way, 4 of them phase 3. Seizures · UCB S.A..
Among the 40 studies in Seizures by UCB S.A., this one is the 36th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2014, is one of 8 in phase 2, and was the 25th registered.
766 studies on the registry are indexed under Seizures; 134 are open to participants now.
Browse Seizures studies →3 of the 40 studies in Seizures by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:
Neurona Therapeutics · Sites in United States
Ages 18–75
UCB Biopharma SRL · Sites in United States, Australia, Bulgaria and 10 more countries
Ages 12+
UCB Biopharma SRL · Sites in United States, Australia, Bulgaria and 9 more countries
Ages 12+
By country, each count listing its studies:
Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 26 · Phase 4 3
First in 2000; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1 is below the median of 64 across 519 interventional studies indexed under Seizures.
Median enrollment 102 across the 36 interventional studies, 516 across the 3 observational. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under UCB BIOSCIENCES, Inc., one of the names counted as UCB S.A.. Under that name alone:
UCB BIOSCIENCES, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
2 of the studies in Seizures by UCB S.A. that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05077904Phase 3UCB Biopharma SRLA Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures | 2027-03-29 |
| NCT05064878Phase 3Zogenix, Inc.A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder. | 2027-11-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 40 studies in Seizures by UCB S.A., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to compare the efficacy of Brivaracetam and Phenytoin, both administered intravenously, in adult subjects experiencing nonconvulsive electrographic seizures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects will receive an acute intravenous (iv) dose of Brivaracetam (BRV) 200 mg as a bolus on Day 1. If seizures recur, a second iv bolus of BRV 100 mg can be given no sooner than 15 minutes after the first bolus. If the second acute bolus is not needed within12 hours after first iv bolus, BRV will be continued as 100 mg iv dose every 12 hours (bid). The total dose for the first 24 hours of treatment should not exceed a maximum dose of 400 mg. The rate of bolus administration is 50 mg (5 mL) undiluted BRV/min. On study Day 5 (or earlier), subjects will transition from iv to oral formulation, at comparable dosing for a maximum of 6 months. Subjects should transition to oral medication as soon as they are able to swallow tablets.
Drug: Brivaracetam intravenous solution · Drug: Brivaracetam oral tablets
Subjects will receive an acute intravenous (iv) dose of Phenytoin (PHT) 20 mg/kg at a rate of 50 mg/min on Day 1. If seizures recur, a second acute dose of PHT iv will be given no sooner than 15 minutes after the first dose. Treatment with PHT iv will be continued with at least 2 daily divided doses according to site practice. Daily PHT dose can be adapted according to investigator's clinical judgment. On study Day 5 (or earlier), subjects will transition from iv to oral formulation at comparable dosing for a maximum of 6 months. Subjects should transition to oral medication as soon as they are able to swallow tablets.
Drug: Phenytoin intravenous solution · Drug: Phenytoin oral tablets
* Active Substance: Brivaracetam * Pharmaceutical Form: Solution for infusion * Concentration: 10 mg/mL * Route of Administration: Intravenous bolus use
* Active Substance: Brivaracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 10 mg and 25 mg tablets; Daily Dose: 200 mg/day (100 mg bid) * Route of Administration: Oral use
* Active Substance: Phenytoin * Pharmaceutical Form: Solution for infusion * Concentration: 50 mg/mL * Route of Administration: Intravenous use
* Active Substance: Phenytoin * Pharmaceutical Form: Tablet * Concentration: Weight based * Route of Administration: Oral use
Percentage of Subjects With Seizure Freedom for 12 Hours Based on cEEG/vEEG Monitoring Which Starts 1 Hour After the End of the Last Acute iv Administration of Study Drug and Prior to the Initiation of Bid (Twice a Day) Dosing
Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.
Time frame: From 1 hour after end of the last acute iv administration of study drug and prior to initiation of bid dosing (which begins 12 hours after the last acute iv administration of study drug)
Percentage of Subjects With Seizure Freedom for 12 Hours Based on cEEG/vEEG Monitoring Which Starts After the End of the Last Acute Intravenous (iv) Administration of Study Drug and Prior to the Initiation of Bid (Twice a Day) Dosing
Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.
Time frame: From end of the last acute iv administration of study drug and prior to initiation of bid dosing (which begins 12 hours after the last acute iv administration of study drug)
Time to Achievement of 12 Hours of Seizure Freedom Relative to the Start of the First Acute Intravenous (iv) Administration
Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.
Time frame: From start of first acute iv administration on Day 1
Time to Achievement of 12 Hours of Seizure Freedom Relative to the Start of the Last Acute Intravenous (iv) Administration That Occurred Prior to the Initiation of Bid (Twice a Day) Dosing
Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.
Time frame: From start of last acute iv administration prior to initiation of bid dosing (which begins 12 hours after the last acute iv administration of study drug)
Percentage of Subjects Requiring a Second Acute Intravenous (iv) Administration Between 15 Minutes to 12 Hours After First Acute iv Administration
Time frame: Between 15 minutes to 12 hours after first acute iv administration
Time to First Onset of Seizure Cessation Relative to the Start of the First Acute Intravenous (iv) Administration
Seizure cessation is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.
Time frame: From start of first acute iv administration
Sixty subjects were planned to be screened in order to enroll 50 subjects in a 1:1 ratio to intravenous (iv) Brivaracetam (BRV) or iv Phenytoin (PHT) with stratification based on categorized age (\<65 years versus ≥65 years) across approximately 15 sites.
| Milestone | Brivaracetam | Phenytoin |
|---|---|---|
| Started | 1 | 0 |
| Completed | 0 | 0 |
| Not completed | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.
No measurements were reported for this outcome.
Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.
No measurements were reported for this outcome.
Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.
No measurements were reported for this outcome.
Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Seizure cessation is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.
No measurements were reported for this outcome.
Collected over Adverse Events were collected during the 75 days the only subject was included in this study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brivaracetam | — | 0/1 (0%) | 1/1 (100%) |
| Phenytoin | — | — | — |
| Event | Brivaracetam | Phenytoin |
|---|---|---|
| ConstipationGastrointestinal disorders | 1/1 | — |
| Decreased appetiteMetabolism and nutrition disorders | 1/1 | — |
| Decreased urinary outputInvestigations | 1/1 | — |
| iv infiltrationGeneral disorders | 1/1 | — |
| Failure to thriveMetabolism and nutrition disorders | 1/1 | — |
Demographics of the only subject included are presented below.
| Age, Categorical(Participants) | Brivaracetam |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 1 |
| >=65 years | 0 |
| Age, Continuous(years) | Brivaracetam |
|---|---|
| Mean | 18 ± 0 |
| Sex: Female, Male(Participants) | Brivaracetam |
|---|---|
| Female | 1 |
| Male | 0 |
The record gives a start of Mar 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 1 year 6 months after primary completion. A results delay was requested in Jul 2015.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam